ODI Pharma AB (“ODI Pharma” or the ”Company”) published on February 27th the company’s Q2-report for...
Revenues in Q4 came in at SEK10m, slightly softer than we had estimated, albeit still showing growth...
Redeye provides an update on Jumpgate following its weaker-than-expected Q4 results.
Redeye leaves its initial comments on Integrum’s Q3 report.
Svag försäljning men förbättrad lönsamhet Nettoomsättningen minskade med 19,9 procent, främst på gru...
Physitrack’s Q4 2024 report came in stronger on sales than expected but slightly below profitability...
Redeye initiates coverage on GiG Software which is an online gambling platform supplier with an attr...
Surprisingly strong orders support view that cycle has bottomed Soft guidance, but we think company ...
Neovici publiderade den 28 februari bolagets Q4-rapport.
Nettoomsättningen för det fjärde kvartalet uppgick till 1,2 MSEK (0,6), en ökning med 98,0 procent j...
Idag, fredag 28 februari, offentliggjorde Enrad AB (”Enrad” eller ”Bolaget”) sin rapport för kv4 202...
Today on 28 February, Enrad AB (“Enrad” or “the Company”) published its interim report for Q4 2024.
Net sales without extraordinary item was close to market consensus (LSEG) expectations in Q4.
Redeye leaves a research update following Klaria Pharma’s recently published Q4 2024 report.
Björn Borg (“Björn Borg”, “the Company” or “the Group”) is a well-established and renowned company w...
The report was overall weaker than expected, primarily due to three out of four segments underperfor...
Aixias omsättning steg med 75% till 48 (27,4) mkr i det fjärde kvartalet, men rörelseresultatet uppg...
Revenue growth was -7% in Q4 y/y by excluding the largest customer.
Redeye provides a research update following the Q4 report published by Initiator Pharma earlier toda...
Redeye was hoping for slightly higher Q4 numbers, but quarterly variations are not unusual.
